Text FDA Approved appearing behind ripped brown paper.

The agency granted accelerated approval to Retevmo in RET fusion-positive non-small-cell lung cancer thyroid cancer and RET-mutated medullary thyroid cancer. The company is mounting a virtual rollout effort as sales staff are grounded due to the Covid-19 pandemic, an exec said.

LEAVE A REPLY

Please enter your comment!
Please enter your name here